Evia Life Sciences
EVIA Life Sciences is a biotechnology company that develops cell-free exosome-based therapeutics targeting liver fibrosis and MASH.
Seed ·
Amount not disclosed in a source on record.
Funding history ↓Signals
Website registeredFeb 7, 2020 (6 years old)
Funding rounds
| Date | Round | Amount | Lead | Source |
|---|---|---|---|---|
| Seed | undisclosed | — | sec.gov |
Timeline
- Website created
Founders and team
TO
Takahiro Ochiya FounderKT
Kosuke Takishima CEO
Companies like Evia Life Sciences
GGranite Bio$30M Series A · Apr 2025
PPushCART TherapeuticsSeed · Jul 2026
AArnatar Therapeutics$50M Series A · Mar 2026
RResolution TherapeuticsSeries B+ · Oct 2024
RReCode TherapeuticsSeries B+ · Oct 2023AAbcuro$66M Series B+ · Aug 2026
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/evia-life-sciences (get a free API key).